harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
![Harvard Bioscience logo](/files/LOGO/1123494-HBIO.png)
Company profile
Ticker
HBIO
Exchange
Website
CEO
James W. Green
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biochrom Limited • Biochrom US, Inc. • CMA Microdialysis Ab • Data Sciences International, Inc. • Data Sciences (UK) Mn, Ltd. • Data Sciences GmbH • DSI (Shanghai) Trading Co Ltd. • Harvard Bioscience (Shanghai) Co. Ltd. • Hugo Sachs Elektronik - Harvard Apparatus GmbH • Multichannel Systems MCS GmbH ...
IRS number
43306140
HBIO stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
29 May 24
8-K
Submission of Matters to a Vote of Security Holders
14 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Harvard Bioscience Announces First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
3 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
Transcripts
HBIO
Earnings call transcript
2024 Q1
7 May 24
HBIO
Earnings call transcript
2023 Q4
7 Mar 24
HBIO
Earnings call transcript
2023 Q3
7 Nov 23
HBIO
Earnings call transcript
2023 Q2
8 Aug 23
HBIO
Earnings call transcript
2023 Q2
8 Aug 23
HBIO
Earnings call transcript
2023 Q1
25 Apr 23
HBIO
Earnings call transcript
2022 Q4
9 Mar 23
HBIO
Earnings call transcript
2022 Q3
8 Nov 22
HBIO
Earnings call transcript
2022 Q2
7 Aug 22
HBIO
Earnings call transcript
2022 Q1
4 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm |
Cash burn (monthly) | 9.33 k | (no burn) | 1.49 mm | 718.17 k | (no burn) | (no burn) |
Cash used (since last report) | 36.09 k | n/a | 5.78 mm | 2.78 mm | n/a | n/a |
Cash remaining | 4.22 mm | n/a | -1.52 mm | 1.48 mm | n/a | n/a |
Runway (months of cash) | 452.0 | n/a | -1.0 | 2.1 | n/a | n/a |
Institutional ownership, Q1 2024
10.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 15 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 17.62 bn |
Total shares | 4.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AMH Equity | 2.32 mm | $9.85 bn |
Heartland Advisors | 889.13 k | $3.77 bn |
BK Bank Of New York Mellon | 243.13 k | $1.03 bn |
Greenwood Capital Associates | 216.61 k | $918.44 mm |
New York State Common Retirement Fund | 178.35 k | $756.00 k |
Pasadena Private Wealth | 172.49 k | $731.34 mm |
Riverwater Partners | 93.20 k | $395.16 mm |
Assenagon Asset Management | 77.48 k | $328.53 mm |
BNP Paribas Arbitrage | 75.97 k | $322.11 mm |
Legato Capital Management | 35.03 k | $148.52 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Jun 24 | Green James W | Common Stock | Buy | Acquire P | No | No | 2.91 | 10,000 | 29.10 k | 3,111,091 |
6 Jun 24 | Green James W | Common Stock | Buy | Acquire P | No | No | 3.07 | 20,000 | 61.40 k | 3,101,091 |
21 May 24 | Eade Katherine A. | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 311,126 |
21 May 24 | Loewald Thomas W | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 295,311 |
21 May 24 | Edrick Alan I | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 273,911 |
News
Holley And 2 Other Stocks Under $5 Insiders Are Buying
17 Jun 24
FlexShopper And 3 Other Stocks Under $5 Insiders Are Buying
10 Jun 24
Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens
7 May 24
Harvard Bioscience Q1 Adj $0.02, Inline, Sales $24.51M Miss $25.79M Estimate
7 May 24
Press releases
Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024
6 Jun 24
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
23 May 24
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
16 May 24
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
29 Apr 24